Literature DB >> 34200441

Optimization of Vero Cells Grown on a Polymer Fiber Carrier in a Disposable Bioreactor for Inactivated Coxsackievirus A16 Vaccine Development.

Keda Chen1, Chaonan Li1, Ying Wang1, Zhenwei Shen1, Yikai Guo1, Xiaoping Li1, Yanjun Zhang2.   

Abstract

At present, there are no vaccines available for hand, foot, and mouth disease, which is caused by Coxsackie virus A16 (CVA16) infection. In the present study, we isolated epidemic strains of CVA16 and optimized the production of the virus in Vero cells. The system comprised growing the infected cells on polymer fiber paper carriers in a serum-free medium containing 0.5% (w/v) lactalbumin hydrolysate a mini bioreactor. Disposable Bioflo310 and AmProtein Current perfusion bioreactors were used to monitor virus infection and Vero cell culture. The total number of cells increased from 1.5 × 109 to 3.0 × 1010. In our optimized culture process, the virus titer reached 7.8 × 107 TCID50/mL at three days after infection. The inactivated CVA16 prepared from our optimized culture procedure elicited a slightly higher neutralizing antibody titer compared with that derived from routine culture procedures. These results will promote the large-scale production of inactivated CVA16 vaccines using nonwoven polymer fiber paper cell cultures.

Entities:  

Keywords:  coxsackie virus A16; disposable mini bioreactor; polymer fiber paper carriers; vaccine

Year:  2021        PMID: 34200441     DOI: 10.3390/vaccines9060613

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  3 in total

1.  Development of Next-Generation Vaccines.

Authors:  Takashi Imai
Journal:  Vaccines (Basel)       Date:  2022-02-10

Review 2.  Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects.

Authors:  Zhongbiao Fang; Jingting Lyu; Jianhua Li; Chaonan Li; Yuxuan Zhang; Yikai Guo; Ying Wang; Yanjun Zhang; Keda Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-08-09

3.  A comparison of the test-negative and the matched case-control study designs for estimation of EV71 vaccine immunological surrogate endpoints from a randomized controlled trial.

Authors:  Li Zhang; Pengfei Jin; Mingwei Wei; Hudachuan Jiang; Jingxin Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2022-06-09       Impact factor: 4.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.